Mar. 13 at 9:46 PM
$HIMS $ARKK $SPY
Novo Nordisk Partnership: Branded Wegovy (injections + oral pill) and Ozempic coming to the platform this month. Future product roadmap includes CagriSema (23% weight loss, FDA decision late 2026), amycretin (next-gen oral obesity drug), and a
$2B triple agonist. HIMS is positioned as the consumer distribution channel for the most prolific obesity drug pipeline in the world. Also, Eucalyptus Acquisition:
$1.15B deal for a digital health platform already operating in Australia, UK, Germany, and Japan. The market still sees the old HIMS. The new HIMS is being built in plain sight.
More partnerships coming very soon. 🩳🔥📱